Lexeo Therapeutics (LXEO) EBT: 2022-2023
Historic EBT for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.2 million.
- Lexeo Therapeutics' EBT rose 2.68% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 48.11% down from last year.
- According to the latest figures from Q4 2023, Lexeo Therapeutics' EBT is -$14.2 million, which was up 29.45% from -$20.1 million recorded in Q3 2023.
- Lexeo Therapeutics' EBT's 5-year high stood at -$13.4 million during Q2 2023, with a 5-year trough of -$20.1 million in Q3 2023.
- In the last 2 years, Lexeo Therapeutics' EBT had a median value of -$15.8 million in 2022 and averaged -$16.3 million.
- Examining YoY changes over the last 5 years, Lexeo Therapeutics' EBT showed a top increase of 2.68% in 2023 and a maximum decrease of 17.90% in 2023.
- Over the past 2 years, Lexeo Therapeutics' EBT (Quarterly) stood at -$14.6 million in 2022, then increased by 2.68% to -$14.2 million in 2023.
- Its EBT stands at -$14.2 million for Q4 2023, versus -$20.1 million for Q3 2023 and -$13.4 million for Q2 2023.